Additionally, using several approaches, we show that adoptive transfer of functional B cells, direct manipulation of BA availability in the gut, and ablation of a key enzyme necessary for bacterial BA bio-transformation are all able to modulate the severity of SI enteropathy in CD19−/− mice. The gene discussed is CD19; the disease is Abnormal intestine morphology.